Indaptus Therapeutics announces the addition of Morristown Medical Center, part of the Atlantic Health System, as a new clinical trial site for INDP-D101. INDP-D101 is the Company’s first-in-human, open label, dose escalation and expansion, multicenter Phase 1 clinical trial of its lead compound Decoy20 in patients with advanced/metastatic solid tumors. Patient screening at the Morristown, NJ hospital is expected soon. "The continued expansion of trial sites will help to facilitate a potentially more rapid enrollment and get us to our initial data points, which, in turn will continue to facilitate the development of what we believe is a potentially important innovation in the treatment of solid tumors," said Jeffrey Meckler, Indaptus Therapeutics’ CEO. "We look forward to collaborating closely with the investigators at Morristown Medical Center, and all of clinical trial sites, which we hope to be opening in succession in the coming weeks."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on INDP:
- Indaptus Therapeutics Activates Morristown Medical Center as Trial Site in INDP-D101, Its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors
- Indaptus Therapeutics Announces Initiation of First-In-Human, Open Label, Dose Escalation and Expansion Multicenter Phase 1 Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors
- Indaptus Therapeutics initiates first-in-human Phase 1 trial of Decoy20